Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Equity Average: 2014-2025

Historic Equity Average for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Sep 2025 value amounting to $509.1 million.

  • Viridian Therapeutics, Inc.\DE's Equity Average fell 17.68% to $509.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $509.1 million, marking a year-over-year decrease of 17.68%. This contributed to the annual value of $556.8 million for FY2024, which is 33.04% up from last year.
  • Viridian Therapeutics, Inc.\DE's Equity Average amounted to $509.1 million in Q3 2025, which was down 9.07% from $559.8 million recorded in Q2 2025.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Equity Average peaked at $689.6 million during Q4 2024, and registered a low of $102.5 million during Q2 2021.
  • Moreover, its 3-year median value for Equity Average was $512.3 million (2024), whereas its average is $495.6 million.
  • Its Equity Average has fluctuated over the past 5 years, first surged by 618.98% in 2021, then fell by 17.68% in 2025.
  • Quarterly analysis of 5 years shows Viridian Therapeutics, Inc.\DE's Equity Average stood at $196.2 million in 2021, then soared by 104.96% to $402.0 million in 2022, then decreased by 9.76% to $362.8 million in 2023, then soared by 90.07% to $689.6 million in 2024, then declined by 17.68% to $509.1 million in 2025.
  • Its Equity Average stands at $509.1 million for Q3 2025, versus $559.8 million for Q2 2025 and $638.1 million for Q1 2025.